Industry Educational Session - Dynamics of treatment selection: CLL patient cases discussion - Sponsored by Astrazeneca
Tracks
Track 5
| Tuesday, April 30, 2024 |
| 12:20 PM - 1:05 PM |
| Room 12 |
Details
• The significance of genetic screening and its role in supporting effective treatment decision-making
• Considerations for choosing finite versus continuous treatment for long-term disease control
• Differentiation of second-generation BTKis
Speaker
Dr. Becky Allchin
Consultant Haematologist
University Hospitals Of Leicester
-
Dr. Edward Bataillard
Haem Consultant
Hammersmith Hospital
-
Professor Adrian Bloor
Consultant Haematologist And Mahsc Honorary Clinical Chair (university Of Manchester) Director Of Stem Cell Transplantation Divisional Medical Director – Network Services
The Christie NHS Foundation Trust
-
Dr Helen Marr
Consultant Haematologist
Freeman Hospital, Newcastle
-
